Perceptive Life Sciences Master Fund Ltd - Net Worth and Insider Trading
Perceptive Life Sciences Master Fund Ltd Net Worth
The estimated net worth of Perceptive Life Sciences Master Fund Ltd is at least $3.3 Billion dollars as of 2024-10-09. Perceptive Life Sciences Master Fund Ltd is the 10% Owner of Prometheus Biosciences Inc and owns about 3,314,032 shares of Prometheus Biosciences Inc (RXDX) stock worth over $663 Million. Perceptive Life Sciences Master Fund Ltd is the Director of Cerevel Therapeutics Holdings Inc and owns about 10,965,193 shares of Cerevel Therapeutics Holdings Inc (CERE) stock worth over $493 Million. Perceptive Life Sciences Master Fund Ltd is also the 10% Owner of Global Blood Therapeutics Inc and owns about 4,889,066 shares of Global Blood Therapeutics Inc (GBT) stock worth over $335 Million. Besides these, Perceptive Life Sciences Master Fund Ltd also holds ADMA Biologics Inc (ADMA) , Crinetics Pharmaceuticals Inc (CRNX) , Amicus Therapeutics Inc (FOLD) , Soleno Therapeutics Inc (SLNO) , Kadmon Holdings Inc (KDMN) , Zogenix Inc (ZGNX) , Dova Pharmaceuticals Inc (DOVA) , Albireo Pharma Inc (ALBO) , Astria Therapeutics Inc (ATXS) , MeiraGTx Holdings PLC (MGTX) , Aldeyra Therapeutics Inc (ALDX) , Solid Biosciences Inc (SLDB) , Landos Biopharma Inc (LABP) , Acrivon Therapeutics Inc (ACRV) , Corium International Inc (CORI) , Nautilus Biotechnology Inc (NAUT) , LianBio (LIANY) , La Jolla Pharmaceutical Co (LJPC) , Verrica Pharmaceuticals Inc (VRCA) , Cargo Therapeutics Inc (CRGX) , IsoPlexis Corp (ISO) , Rain Oncology Inc (RAIN) , SCYNEXIS Inc (SCYX) , Athira Pharma Inc (ATHA) , Leap Therapeutics Inc (LPTX) , ARYA Sciences Acquisition Corp II (ARYB) , VYNE Therapeutics Inc (VYNE) , Lyra Therapeutics Inc (LYRA) , Talphera Inc (TLPH) , VBI Vaccines Inc (VBIVQ) , Agile Therapeutics Inc (AGRX) , Aravive Inc (ARAV) , Athenex Inc (ATNXQ) , Quotient Ltd (QTNTQ) , Motus GI Holdings Inc (MOTS) . Details can be seen in Perceptive Life Sciences Master Fund Ltd's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Perceptive Life Sciences Master Fund Ltd has not made any transactions after 2024-08-12 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Perceptive Life Sciences Master Fund Ltd
Perceptive Life Sciences Master Fund Ltd Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Perceptive Life Sciences Master Fund Ltd owns 43 companies in total, including ARYA Sciences Acquisition Corp II (ARYBU) , Athira Pharma Inc (ATHA) , and Quotient Ltd (QTNTQ) among others .
Insider Ownership Summary of Perceptive Life Sciences Master Fund Ltd
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
ARYBU | ARYA Sciences Acquisition Corp II | 2020-10-20 | director |
ATHA | Athira Pharma Inc | 2023-12-29 | 10 percent owner |
QTNTQ | Quotient Ltd | 2022-10-31 | 10 percent owner |
2020-09-14 | 10 percent owner | ||
2022-10-13 | 10 percent owner | ||
2024-04-05 | 10 percent owner | ||
2020-06-22 | 10 percent owner | ||
2021-08-16 | 10 percent owner | ||
2023-05-31 | 10 percent owner | ||
2023-04-06 | 10 percent owner | ||
2022-04-18 | 10 percent owner | ||
2021-09-30 | 10 percent owner | ||
2021-10-13 | 10 percent owner | ||
2019-11-18 | 10 percent owner | ||
2019-11-12 | 10 percent owner | ||
2024-08-12 | director & 10 percent owner | ||
2019-07-29 | 10 percent owner | ||
2024-01-11 | director & 10 percent owner | ||
2021-01-22 | 10 percent owner | ||
2018-10-03 | 10 percent owner | ||
2019-01-08 | 10 percent owner | ||
2018-10-12 | 10 percent owner | ||
2018-08-10 | 10 percent owner | ||
2023-12-29 | 10 percent owner | ||
2017-12-19 | 10 percent owner | ||
2017-09-22 | 10 percent owner | ||
2017-06-19 | 10 percent owner | ||
2013-06-15 | 10 percent owner | ||
2011-07-01 | 10 percent owner | ||
2008-01-03 | 10 percent owner | ||
2003-08-04 | 10 percent owner & other: Managing Member | ||
2004-02-06 | 10 percent owner | ||
2021-01-22 | 10 percent owner | ||
2024-02-01 | director & 10 percent owner | ||
2021-10-12 | 10 percent owner | ||
2021-03-16 | 10 percent owner | ||
2021-10-12 | 10 percent owner | ||
2021-08-27 | director | ||
2023-10-16 | director | ||
2021-12-08 | 10 percent owner | ||
2022-08-18 | 10 percent owner | ||
2024-04-11 | 10 percent owner | ||
2023-09-28 | 10 percent owner |
Perceptive Life Sciences Master Fund Ltd Latest Holdings Summary
Perceptive Life Sciences Master Fund Ltd currently owns a total of 38 stocks. Among these stocks, Perceptive Life Sciences Master Fund Ltd owns 3,314,032 shares of Prometheus Biosciences Inc (RXDX) as of March 16, 2021, with a value of $663 Million and a weighting of 20.33%. Perceptive Life Sciences Master Fund Ltd owns 10,965,193 shares of Cerevel Therapeutics Holdings Inc (CERE) as of October 16, 2023, with a value of $493 Million and a weighting of 15.13%. Perceptive Life Sciences Master Fund Ltd also owns 4,889,066 shares of Global Blood Therapeutics Inc (GBT) as of December 19, 2017, with a value of $335 Million and a weighting of 10.28%. The other 35 stocks ADMA Biologics Inc (ADMA) , Crinetics Pharmaceuticals Inc (CRNX) , Amicus Therapeutics Inc (FOLD) , Soleno Therapeutics Inc (SLNO) , Kadmon Holdings Inc (KDMN) , Zogenix Inc (ZGNX) , Dova Pharmaceuticals Inc (DOVA) , Albireo Pharma Inc (ALBO) , Astria Therapeutics Inc (ATXS) , MeiraGTx Holdings PLC (MGTX) , Aldeyra Therapeutics Inc (ALDX) , Solid Biosciences Inc (SLDB) , Landos Biopharma Inc (LABP) , Acrivon Therapeutics Inc (ACRV) , Corium International Inc (CORI) , Nautilus Biotechnology Inc (NAUT) , LianBio (LIANY) , La Jolla Pharmaceutical Co (LJPC) , Verrica Pharmaceuticals Inc (VRCA) , Cargo Therapeutics Inc (CRGX) , IsoPlexis Corp (ISO) , Rain Oncology Inc (RAIN) , SCYNEXIS Inc (SCYX) , Athira Pharma Inc (ATHA) , Leap Therapeutics Inc (LPTX) , ARYA Sciences Acquisition Corp II (ARYB) , VYNE Therapeutics Inc (VYNE) , Lyra Therapeutics Inc (LYRA) , Talphera Inc (TLPH) , VBI Vaccines Inc (VBIVQ) , Agile Therapeutics Inc (AGRX) , Aravive Inc (ARAV) , Athenex Inc (ATNXQ) , Quotient Ltd (QTNTQ) , Motus GI Holdings Inc (MOTS) have a combined weighting of 54.27% among all his current holdings.
Latest Holdings of Perceptive Life Sciences Master Fund Ltd
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
RXDX | Prometheus Biosciences Inc | 2021-03-16 | 3,314,032 | 199.92 | 662,541,277 |
CERE | Cerevel Therapeutics Holdings Inc | 2023-10-16 | 10,965,193 | 44.96 | 492,995,077 |
GBT | Global Blood Therapeutics Inc | 2017-12-19 | 4,889,066 | 68.49 | 334,852,130 |
ADMA | ADMA Biologics Inc | 2021-09-30 | 13,262,375 | 20.91 | 277,316,261 |
CRNX | Crinetics Pharmaceuticals Inc | 2022-04-18 | 5,321,032 | 50.44 | 268,392,854 |
FOLD | Amicus Therapeutics Inc | 2018-10-03 | 20,724,424 | 10.10 | 209,316,682 |
SLNO | Soleno Therapeutics Inc | 2023-09-28 | 3,074,542 | 51.03 | 156,893,878 |
KDMN | Kadmon Holdings Inc | 2019-11-18 | 14,636,334 | 9.50 | 139,045,173 |
ZGNX | Zogenix Inc | 2018-08-10 | 4,070,357 | 26.68 | 108,597,125 |
DOVA | Dova Pharmaceuticals Inc | 2019-07-11 | 3,708,705 | 28.04 | 103,992,088 |
ALBO | Albireo Pharma Inc | 2022-10-13 | 1,939,723 | 44.15 | 85,638,770 |
ATXS | Astria Therapeutics Inc | 2024-02-01 | 6,485,420 | 10.91 | 70,755,932 |
MGTX | MeiraGTx Holdings PLC | 2024-08-12 | 12,531,103 | 4.15 | 52,004,077 |
ALDX | Aldeyra Therapeutics Inc | 2024-04-05 | 9,275,851 | 5.24 | 48,559,080 |
SLDB | Solid Biosciences Inc | 2024-01-11 | 6,906,646 | 6.96 | 48,070,256 |
LABP | Landos Biopharma Inc | 2021-02-09 | 1,796,084 | 22.93 | 41,184,206 |
ACRV | Acrivon Therapeutics Inc | 2024-04-11 | 5,360,858 | 7.02 | 37,606,419 |
CORI | Corium International Inc | 2018-10-12 | 2,724,686 | 12.68 | 34,549,018 |
NAUT | Nautilus Biotechnology Inc | 2021-12-08 | 9,111,151 | 2.82 | 25,693,446 |
LIANY | LianBio | 2022-08-18 | 53,829,960 | 0.29 | 15,651,061 |
LJPC | La Jolla Pharmaceutical Co | 2019-01-08 | 2,253,376 | 6.22 | 14,015,999 |
VRCA | Verrica Pharmaceuticals Inc | 2023-12-29 | 7,099,182 | 1.29 | 9,154,395 |
CRGX | Cargo Therapeutics Inc | 2023-11-14 | 333,333 | 18.94 | 6,313,327 |
ISO | IsoPlexis Corp | 2021-10-12 | 4,095,498 | 0.76 | 3,119,131 |
RAIN | Rain Oncology Inc | 2021-10-12 | 2,487,019 | 1.21 | 3,009,293 |
SCYX | SCYNEXIS Inc | 2021-01-22 | 1,800,000 | 1.50 | 2,692,080 |
ATHA | Athira Pharma Inc | 2023-12-29 | 5,402,964 | 0.42 | 2,268,705 |
LPTX | Leap Therapeutics Inc | 2020-06-22 | 847,650 | 2.37 | 2,006,642 |
ARYB | ARYA Sciences Acquisition Corp II | 2020-10-21 | 157,295 | 10.10 | 1,588,680 |
VYNE | VYNE Therapeutics Inc | 2021-08-16 | 274,170 | 1.83 | 501,731 |
LYRA | Lyra Therapeutics Inc | 2023-05-31 | 1,288,446 | 0.22 | 286,550 |
TLPH | Talphera Inc | 2017-06-19 | 226,686 | 0.81 | 183,593 |
VBIVQ | VBI Vaccines Inc | 2023-04-06 | 1,381,356 | 0.01 | 17,267 |
AGRX | Agile Therapeutics Inc | 2021-10-13 | 10,827 | 1.51 | 16,349 |
ARAV | Aravive Inc | 2017-09-22 | 349,928 | 0.04 | 14,032 |
ATNXQ | Athenex Inc | 2020-09-14 | 676,623 | 0.02 | 10,285 |
QTNTQ | Quotient Ltd | 2022-10-31 | 198,630 | 0.04 | 7,747 |
MOTS | Motus GI Holdings Inc | 2021-01-22 | 8,868 | 0.04 | 318 |
Holding Weightings of Perceptive Life Sciences Master Fund Ltd
Perceptive Life Sciences Master Fund Ltd Form 4 Trading Tracker
According to the SEC Form 4 filings, Perceptive Life Sciences Master Fund Ltd has made a total of 1 transactions in Prometheus Biosciences Inc (RXDX) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Prometheus Biosciences Inc is the acquisition of 850,000 shares on March 16, 2021, which cost Perceptive Life Sciences Master Fund Ltd around $16 Million.
According to the SEC Form 4 filings, Perceptive Life Sciences Master Fund Ltd has made a total of 5 transactions in Cerevel Therapeutics Holdings Inc (CERE) over the past 5 years, including 5 buys and 0 sells. The most-recent trade in Cerevel Therapeutics Holdings Inc is the acquisition of 876,808 shares on October 16, 2023, which cost Perceptive Life Sciences Master Fund Ltd around $20 Million.
According to the SEC Form 4 filings, Perceptive Life Sciences Master Fund Ltd has made a total of 0 transactions in Global Blood Therapeutics Inc (GBT) over the past 5 years. The most-recent trade in Global Blood Therapeutics Inc is the acquisition of 175,000 shares on December 19, 2017, which cost Perceptive Life Sciences Master Fund Ltd around $7 Million.
More details on Perceptive Life Sciences Master Fund Ltd's insider transactions can be found in the Insider Trading History of Perceptive Life Sciences Master Fund Ltd table.Insider Trading History of Perceptive Life Sciences Master Fund Ltd
- 1
Perceptive Life Sciences Master Fund Ltd Trading Performance
GuruFocus tracks the stock performance after each of Perceptive Life Sciences Master Fund Ltd's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Perceptive Life Sciences Master Fund Ltd is 10.25%. GuruFocus also compares Perceptive Life Sciences Master Fund Ltd's trading performance to market benchmark return within the same time period. The performance of stocks bought by Perceptive Life Sciences Master Fund Ltd within 3 months outperforms 67 times out of 140 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Perceptive Life Sciences Master Fund Ltd's insider trading performs compared to the benchmark.
Performance of Perceptive Life Sciences Master Fund Ltd
Perceptive Life Sciences Master Fund Ltd Ownership Network
Perceptive Life Sciences Master Fund Ltd Owned Company Details
What does ARYA Sciences Acquisition Corp II do?
Who are the key executives at ARYA Sciences Acquisition Corp II?
Perceptive Life Sciences Master Fund Ltd is the director of ARYA Sciences Acquisition Corp II. Other key executives at ARYA Sciences Acquisition Corp II include director & Chief Executive Officer Adam Leo Stone , director & Chief Financial Officer Michael Seth Altman , and 10 percent owner Arya Sciences Holdings Ii .
ARYA Sciences Acquisition Corp II (ARYBU) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of ARYA Sciences Acquisition Corp II (ARYBU) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of ARYA Sciences Acquisition Corp II (ARYBU) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
ARYA Sciences Acquisition Corp II (ARYBU)'s detailed insider trading history can be found in Insider Trading Tracker table.
ARYA Sciences Acquisition Corp II Insider Transactions
Perceptive Life Sciences Master Fund Ltd Mailing Address
Above is the net worth, insider trading, and ownership report for Perceptive Life Sciences Master Fund Ltd. You might contact Perceptive Life Sciences Master Fund Ltd via mailing address: C/o Perceptive Advisors Llc, 51 Astor Place, 10th Floor, New York Ny 10003.